[go: up one dir, main page]

EP3998255A4 - Petite molécule régulatrice de tlr8 - Google Patents

Petite molécule régulatrice de tlr8 Download PDF

Info

Publication number
EP3998255A4
EP3998255A4 EP20835516.4A EP20835516A EP3998255A4 EP 3998255 A4 EP3998255 A4 EP 3998255A4 EP 20835516 A EP20835516 A EP 20835516A EP 3998255 A4 EP3998255 A4 EP 3998255A4
Authority
EP
European Patent Office
Prior art keywords
regulatory molecule
small regulatory
tlr8
tlr8 small
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20835516.4A
Other languages
German (de)
English (en)
Other versions
EP3998255A1 (fr
Inventor
Hang Hubert Yin
Shuangshuang Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Original Assignee
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University filed Critical Tsinghua University
Publication of EP3998255A1 publication Critical patent/EP3998255A1/fr
Publication of EP3998255A4 publication Critical patent/EP3998255A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20835516.4A 2019-07-01 2020-06-22 Petite molécule régulatrice de tlr8 Pending EP3998255A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910585582.7A CN112174903B (zh) 2019-07-01 2019-07-01 Tlr8的小分子调节剂
PCT/CN2020/097340 WO2021000755A1 (fr) 2019-07-01 2020-06-22 Petite molécule régulatrice de tlr8

Publications (2)

Publication Number Publication Date
EP3998255A1 EP3998255A1 (fr) 2022-05-18
EP3998255A4 true EP3998255A4 (fr) 2023-07-26

Family

ID=73914693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20835516.4A Pending EP3998255A4 (fr) 2019-07-01 2020-06-22 Petite molécule régulatrice de tlr8

Country Status (4)

Country Link
US (1) US20230002327A1 (fr)
EP (1) EP3998255A4 (fr)
CN (1) CN112174903B (fr)
WO (1) WO2021000755A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112920131A (zh) * 2021-03-03 2021-06-08 天津医科大学 一类1,2,4-三氮唑衍生物及其制法和用途
CN119822994A (zh) * 2024-12-16 2025-04-15 华南理工大学 用于单组分湿固化聚氨酯涂料的含酰胺键扩链剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380888A1 (fr) * 2002-07-11 2004-01-14 Eastman Kodak Company Matériaux photothermographiques noir-et-blanc contenant des toners mercaptotriazoles
WO2004089367A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de 1,2,4-triazoles substituees
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
WO2014037751A1 (fr) * 2012-09-07 2014-03-13 Cancer Research Technology Limited Composés pharmacologiquement actifs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
WO2009030996A1 (fr) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés triazole utilisés comme agonistes du récepteur de type toll (tlr)
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
JP2013133284A (ja) * 2011-12-26 2013-07-08 Sumitomo Chemical Co Ltd ε−カプロラクタムの製造方法
PL3134402T3 (pl) * 2014-04-22 2020-11-02 F.Hoffmann-La Roche Ag Związki 4-amino-imidazochinolinowe
HUE038059T2 (hu) 2015-03-04 2018-10-29 Gilead Sciences Inc Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
WO2017034986A1 (fr) 2015-08-21 2017-03-02 University Of Kansas Agonistes de sélection de tlr8 humains
EP3210469A1 (fr) * 2016-02-23 2017-08-30 Bayer Cropscience AG Utilisation des thio-1,2,4-triazoles substitués pour augmenter le tolerance de stress dans des plants
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP2018135270A (ja) * 2017-02-20 2018-08-30 大日本住友製薬株式会社 イミダゾール誘導体
WO2018233648A1 (fr) 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 Dérivé d'isothiazolo[4,3-d]pyrimidine-5,7-diamine utilisé en tant qu'agoniste de tlr8
US11466010B2 (en) 2017-10-30 2022-10-11 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380888A1 (fr) * 2002-07-11 2004-01-14 Eastman Kodak Company Matériaux photothermographiques noir-et-blanc contenant des toners mercaptotriazoles
WO2004089367A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de 1,2,4-triazoles substituees
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
WO2014037751A1 (fr) * 2012-09-07 2014-03-13 Cancer Research Technology Limited Composés pharmacologiquement actifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021000755A1 *

Also Published As

Publication number Publication date
CN112174903B (zh) 2022-07-12
WO2021000755A1 (fr) 2021-01-07
CN112174903A (zh) 2021-01-05
US20230002327A1 (en) 2023-01-05
EP3998255A1 (fr) 2022-05-18

Similar Documents

Publication Publication Date Title
DK3652215T3 (da) Forbedret polypeptidmolekyle med dobbelt specificitet
MA47680A (fr) Arn thérapeutique
PT3649151T (pt) Proteínas de suporte
MA44479A (fr) Arn transrepliquant
EP3328394A4 (fr) Arn épitope peptidiques concatémériques
MA55746A (fr) Molécules multispécifiques ciblant cll-1
EP3347035A4 (fr) Peptides localisant le cartilage
EP3719036A4 (fr) Molécule de liaison à un ligand ayant une activité de liaison à un ligand réglable
DE112016005206A5 (de) Farbspritzgerät
DK3416974T3 (da) Proteinoprensning
EP3969844C0 (fr) Support de roue
EP3689999A4 (fr) Pulvérisateur
EP3560252C0 (fr) Schéma de réception
EP3623174A4 (fr) Pneu non pneumatique
EP3673066A4 (fr) Molécules d'arn
EP3972855A4 (fr) Roue omnidirectionnelle tolérante aux chocs
EP3623175A4 (fr) Pneu non pneumatique
EP4025013A4 (fr) Pare-brise
EP3847413C0 (fr) Support de roue
EP3725417A4 (fr) Extension isolée pour pulvérisation avec assistance électrostatique
EP3604465A4 (fr) Composition de matériau de revêtement par électrodéposition cationique
EP3998255A4 (fr) Petite molécule régulatrice de tlr8
EP3494804C0 (fr) 3-fucosyllactose séché en pulvérisation
DK3606953T3 (da) Fgfr3-bindende molekyler
EP3955702A4 (fr) Pare-brise

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230623

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20230619BHEP

Ipc: A61P 25/28 20060101ALI20230619BHEP

Ipc: A61P 25/00 20060101ALI20230619BHEP

Ipc: A61P 29/00 20060101ALI20230619BHEP

Ipc: A61P 19/02 20060101ALI20230619BHEP

Ipc: A61P 1/04 20060101ALI20230619BHEP

Ipc: A61K 31/4196 20060101ALI20230619BHEP

Ipc: A61K 31/4164 20060101ALI20230619BHEP

Ipc: C07D 401/04 20060101ALI20230619BHEP

Ipc: C07D 233/90 20060101ALI20230619BHEP

Ipc: C07D 233/68 20060101ALI20230619BHEP

Ipc: C07D 233/64 20060101ALI20230619BHEP

Ipc: C07D 249/12 20060101AFI20230619BHEP